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A signiﬁcant number of well-differentiated thyroid cancers progress or recur, becoming
resistant to current therapeutic options. Mouse models recapitulating the genetic and
histological features of advanced thyroid cancer have been an invaluable tool to dissect
the mechanisms involved in the progression from indolent, well differentiated tumors to
aggressive, poorly differentiated carcinomas, and to identify novel therapeutic targets. In
this review, we focus on the lessons learned from models of epithelial cell-derived thyroid
cancer showing progression from hyperplastic lesions to locally invasive and metastatic
carcinomas.
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INTRODUCTION
The thyroid gland is the most common target of neoplastic trans-
formation among endocrine organs. Contrary to most tumor
types, the global incidence of thyroid cancer has been steadily
growing in recent years. Most thyroid cancers derive from the
thyrocytes, the epithelial cells that delineate the thyroid folli-
cles, and include well-differentiated tumors, such as papillary and
follicular carcinomas, as well as poorly differentiated and anaplas-
tic carcinomas. Although well-differentiated thyroid cancers have
generally a goodprognosis and can be effectivelymanaged through
a combination of surgery and radioactive iodine treatment, a
number of them will progress or recur, becoming resistant to
current therapeutic options. On the other hand, poorly differ-
entiated and anaplastic tumors often derive from pre-existing
well-differentiated lesions and are responsible for the vastmajority
of thyroid cancer-related deaths, thanks to their very poor response
to therapy.
In order to design rational approaches to these otherwise
unresponsive tumors, we need to better deﬁne and understand
the molecular mechanisms leading to progression from indolent,
well-differentiated tumors to aggressive cancers. One strategy to
accomplish this task is to generate model systems that more or less
faithfully recapitulate in vivo what has been learned from mol-
ecular pathology studies on patient material. These models can
then be used to dissect in a physiological setting the pathways
deregulated as a consequence of speciﬁc genetic alterations.
Advances in the genetic manipulation of the mouse genome
have facilitated the generationofmodels harboringdeﬁned genetic
alterations that can be controlled both temporally and spatially.
Although their use in preclinical studies is often hampered by the
time needed to develop tumors, by the generally low metastasis
incidence, and by some biological differences between mice and
humans in drug metabolism, mouse models of cancer have been
an invaluable tool to study gene function, interaction between
pathways, and the speciﬁc mechanisms that play a role in tumor
progression.
In this review, we will focus on what we have learned from
mouse models of thyroid cancer that display progression from
hyperplastic lesions to locally invasive and metastatic carcinomas.
PTC PROGRESSION MODELS
Papillary thyroid carcinoma (PTC) is the most common subtype
among differentiated thyroid tumors and represents up to 80% of
all malignant thyroid cancers. Patients affected by PTC are effec-
tively treated with thyroidectomy followed by radioactive iodine
ablation (DeGroot et al., 1990). After surgery the survival rate and
the therapeutic outcomes of PTC patients are favorable. However,
up to 10% of PTC patients can exhibit lymph node metastases or
distant metastases at the time of thyroid ablation that are associ-
ated with a signiﬁcant increase in morbidity (Huang et al., 2011).
The etiology of papillary carcinomas is often correlated with a diet
poor in iodine and with radiation exposure. In particular there
are evidences that survivors of cancers of various organs whose
tumor had been treated with radiation developed, later on in
their life, papillary thyroid cancers (LiVolsi, 2011). Older age,male
sex, large size, and extrathyroidal extension can be a contributing
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factor for a negative prognosis, although they are not entirely reli-
able in predicting tumor recurrence,metastasis, and cancer-related
death. The diagnosis for PTCs is based on conventional tumor
morphology and on theWHO histological classiﬁcation (Kakudo
et al., 2011). This classiﬁcation is based on nuclear features such
as ground glass appearance, pale staining, inconspicuous nucle-
oli, large size, and irregular outline together with the presence
of vascular core, psammoma bodies, ﬁbrous stroma, squamous
metaplasia, and presence of follicles (LiVolsi and Baloch, 2004).
A minority of PTCs progress from well-differentiated carcinoma
to either poorly or undifferentiated carcinoma, an event asso-
ciated with a marked reduction in survival. However, whether
certain subtypes of papillary carcinoma are associated with a
more aggressive clinical behavior is still unclear. Moreover the
invasive features are often difﬁcult to predict only from the his-
tological analysis. There is increasing evidence suggesting that
PTCs represents a rather heterogeneous group of tumors, and
that speciﬁc genetic alterations may not only determine the dis-
tinct global expression proﬁle of the tumor, but also inﬂuence
its histologic variants and tumor behavior (Giuffrida and Gharib,
2000).
Over the past decade, the genetic and epigenetic basis for PTCs
has been deﬁned and distinct activating mutations of oncogenes
have being described together with epigenetic silencing of tumor
suppressor genes (Kimura et al., 2003). The earliest, most com-
mon, and best-characterized somatic genetic alterations in PTCs
are the RET/PTC rearrangement (Santoro et al., 1993), the TRK-
T1 mutation, and the BRAFV600E point mutation. They appear to
bemutually exclusive, but it has been demonstrated that they work
along the same signaling cascade that starts with the phosphory-
lation of RET on tyrosine 1062, and sequentially triggers RAS,
BRAF, and ERK stimulation. Moreover the three activated onco-
proteins induce largely overlapping gene expression signatures
(Melillo et al., 2005).
The acquisition of amigratory phenotype and the loss of tumor
suppressor genes such as TP53, lead to progression toward poorly
differentiated (PDTC), and undifferentiated thyroid carcinoma
(ATC; Giordano et al., 2005).
Transgenic mice carrying the aforementioned mutations have
been instrumental in increasing our understanding of the mecha-
nisms that are responsible for the progression from PTC to PDTC
or ATC.
RET/PTC MODELS
RET/PTC mutations are frequently detected in PTC, particularly
in radiation-induced PTC. The RET/PTC rearrangement is the
second most common type of genetic alteration known to occur
in thyroid papillary carcinomas (Pierotti et al., 1996).
The RET proto-oncogene encodes a transmembrane glycopro-
tein belonging to the receptor tyrosine kinase (RTK) family. It is
the receptor for growth factors belonging to the glial cell line-
derived neurotrophic factor (GDNF) family. The fusion of the
3′-terminal kinase-encoding domain of RET to the 5′-terminal
regions of heterologous genes leads to the formation of a chimeric
oncogene. There are at least 15 differentRET/PTC rearrangements
but RET/PTC1 and RET/PTC3 are the most prevalent variants.
RET/PTC1 originates from the fusion between RET and the H4
gene (Grieco et al., 1990), while RET/PTC3 originates from the
RET-RFG (also designed as ELE1, NCOA4, ARA70) fusion (San-
toro et al., 1994). All the other rearrangement variants have been
isolated just in rare cases (Fusco and Santoro, 2007).
While the RET proto-oncogene products localize in the mem-
brane fraction and are not phosphorylated in the absence of
a ligand, the RET/PTC product localizes in a soluble cytoplas-
mic fraction and is constitutively phosphorylated (Ishizaka et al.,
1992). RET triggers several intracellular signaling cascades, which
regulate survival, differentiation, proliferation, migration, and
chemotaxis through the activation of targets such as the Ras/ERK
kinase,PI3 kinase/AKT,p38MAPkinase,PLC-γ, JNK,STAT,ERK5,
and Src signaling pathways (Sariola and Saarma, 2003).
RET /PTC3 is more efﬁcient thanRET/PTC1 in promoting pro-
liferation of cultured thyroid cells. Accordingly, transgenic mice
expressing the human RET/PTC1 gene under the control of the
bovine thyroglobulin promoter develop PTCs, demonstrating that
RET/PTC oncogenes are able to initiate thyroid carcinogenesis
(Santoro et al., 1996). However, invasive cancer does not occur in
these models. On the other hand, transgenic mice expressing the
human RET/PTC3 gene under the control of the same bovine thy-
roglobulin promoter develop papillary carcinoma with metastatic
spread in selected cases (Jhiang et al., 1998; Powell et al., 1998). The
severity of disease varies markedly between high- and low-copy
number founder lines. High-copy lines have dysplastic thyroid
glands at birth and develop carcinomas as young as 4 days of age,
as compared with 1–6months of age in the low-copy line (Cho
et al., 1999).
RET/PTC1 mice maintained on a low iodine diet present a
persistent elevation of thyroid-stimulating hormone (TSH) lev-
els and enhanced tumorigenesis. However, the high TSH levels of
theRET/PTC1 transgene are a disadvantage of this model, because
chronic TSH stimulation is generally not involved in papillary car-
cinoma development in humans (Williams et al., 2004), although
recent data seem to suggest a correlation between TSH levels and
tumor size (Zafon et al., 2012).
One possibility that could explain the limited ability of small
tumors with RET gene rearrangements to progress, is the pro-
apoptotic activity of RET/PTC. It has been shown that during
tumor progression, secondary events, such as overexpression of
the anti-apoptotic protein Bcl-2 or activation of other cell survival
pathways (Gimm et al., 2001), including overexpression of AKT or
downregulation of PTEN, can be selected to suppress RET/PTC-
induced apoptosis and to promote the expansion of the neoplastic
clones (Castellone et al., 2003).
An additional event that could suppress apoptosis and allow
tumor progression is loss of p53. In general, lack of functional
p53 protein alone is not sufﬁcient to induce a malignant pheno-
type (Battista et al., 1995), however, p53 loss in the presence of
RET /PTC1 mutation contributes to the progression and metas-
tasis formation of thyroid epithelial neoplasms. Transgenic mice
expressing RET/PTC1 under the control of the bovine or rat thy-
roglobulin promoters in a p53−/− background develop anaplastic-
like tumors. These tumors are bilateral, and TSH-responsive, with
cystic and solid regions. The solid regions are composed of spin-
dle cells, which is a common feature of ATCs in human (La Perle
et al., 2000). One caveat of this model is that compound mutant
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mice often died because of extrathyroidal tumors, due to the“non-
tissue-speciﬁc” p53 mutation. Unfortunately a thyroid-restricted
RET/PTC1, p53-/- mouse model does not exist yet. The generation
of this mouse model would likely allow the mice to live enough
for metastases to develop.
The more aggressive RET/PTC3 transgenic mice develop fol-
licular cell hyperplasia and a solid variant of PTC by the age of
6months (Powell et al., 1998). Less than 10%of thesemice develop
metastases to cervical lymph nodes. Interestingly, RET/PTC3 thy-
roids expressed proinﬂammatory genes and cytokines such as
Cox-2, Gmcsf, Il1α, Il1β, Mcp1, Il6, and Tnfα, and recruited
macrophages to the lesions, a process known to aid tumor pro-
gression (Russell et al., 2004). The RET/PTC3-induced thyroid
tumors do not dedifferentiate into a more aggressive phenotype
as often as seen in human patients with RET/PTC3 chromoso-
mal rearrangements. Intercross of Tg-RET/PTC3 transgenic mice
with p53−/−mice results in earlier tumor onset, with microcarci-
noma formation by 3months of age and the development of larger
primary tumors compared to the p53 wild-type mice. However
metastases are still rare (Powell et al., 2001).
TRK-T1 MODELS
The TRK family of oncogenes results from a genetic fusion of the
3′ end of NTRK1 to the 5′ end of several partner genes (Pierotti
et al., 1996). In particular the TRK oncogene results from the
inversion of chromosome 1 that joins the 5′ end of Tropomyosin
(TPM3) to NTRK1 (Bongarzone et al., 1989). TRK-T1, -T2, and
-T4 are generated from inversions of chromosome 1 that join
the 5′ end of TPR to the 3′ end of NTRK1. A rearrangement
involving the genesTFG andNTRK1 results in the family member
TRK-T3.
NTRK1-related translocations have a reported incidence of
about 12%. In vitro, the TRK-T1 oncogene transforms NIH3T3
cells (Greco et al., 1992). The only described mouse model of
NTRK1 rearrangement is a transgenic model of TRK-T1 under
the control of the bovine thyroglobulin promoter. More than 50%
of theTRK-T1mice show thyroid epithelial cell hyperplasia which
progresses to PTCs in animals over 7months of age, and has the
histopathological features observed in its human counterpart.
Few thyroid tumors in TRK-T1 mice developed less-
differentiated solid regions during 24months of observation, and
none of the tumors metastasized. It is clear, as it happens in
RET/PTC mice, that while TRK-T1 predisposes mice to develop
PTCs, additional genetic mutations are required to evolve into
more aggressive tumors (Russell et al., 2000). Thus, the TRK-
T1 fusion gene may allow thyroid follicular epithelial cells to
survive and accumulate other genetic abnormalities. A repre-
sentative example of this concept is the cross between TRK-T1
mice and p27−/− mice. Decreased expression and altered subcel-
lular localization of p27 have been observed in thyroid cancer
(Motti et al., 2005) and a correlation has been found between
the overexpression of the TRK-T1 transgene and p27 deletion in
thyroid carcinomas. The p27 mutation increases the malignant
phenotype of mice expressing the TRK-T1 oncogene: the com-
pound mutants show an increased number of carcinomas with a
shorter latency and an increased proliferation rate (Fedele et al.,
2009).
BRAFV600E MODELS
BRAF is a member of the RAF kinase family. The BRAF gene,
encoding a cytosolic serine–threonine protein kinase, serves as
an immediate downstream effector of RAS. BRAF transmits sig-
nals from RAS to the mitogen-activated protein kinase (MAPK)
pathway through MEK and ERK. Over 30 BRAF mutations asso-
ciated with human cancers have been described, and the majority
is located within the kinase domain. Common BRAF somatic
activating mutations have been identiﬁed in melanomas (70%
prevalence), and colorectal and ovarian cancers (15%), as well
as in thyroid cancers (>40% papillary carcinomas). BRAF muta-
tions are particularly common in melanomas and thyroid cancer.
The growth of melanocytes and thyrocytes is positively regulated
by cAMP. In particular cAMP activates MEK1 and ERK through
mechanisms that converge on BRAF. Thus, BRAF is the key RAF
isoform transducing cAMP-dependent growth signal in both these
cell types (Busca et al., 2000), and this, together with the higher
basal activity and simpler activation mechanism of BRAF com-
pared to ARAF and CRAF (Maurer et al., 2011), can reasonably
explain their vulnerability to transformation by BRAF activating
mutations (Kimura et al., 2003).
The BRAF mutation found in the vast majority of thyroid
cancers is a thymine-to-adenine transversion at nucleotide 1796
(T1796A), resulting in a valine-to-glutamic acid substitution at
amino acid 600 (V600E; Fukushima et al., 2003). BRAF point
mutations are found at all stages of progression, from micro-
carcinomas to poorly differentiated and anaplastic carcinomas,
suggesting that this mutation is responsible for the initiation of
the transformation process.
Thyroid-speciﬁc expression of BRAFV600E induces goiter that
progresses to invasive PTC with tall-cell features. After 22weeks
of age, mice develop aggressive thyroid papillary carcinomas with
a high frequency of invasion into blood vessel, thyroid capsule,
and skeletal muscle (Knauf et al., 2005). BRAF-mutant pap-
illary carcinomas have a high degree of lymphocytic inﬁltra-
tion within the tumor, but less frequent psammoma bodies as
compared to tumors harboring RET/PTC rearrangements. Fur-
thermore, BRAF-mutant tumors have a different gene expres-
sion proﬁle, compared to RET/PTC tumors, with a signiﬁcant
deregulation of genes related to the innate immune response.
There is a strong correlation between increased tumor-associated
macrophages (TAMs) and histologic grade, and between TAMs,
tumor invasiveness, and decreased cancer-related survival in
PDTC. BRAFV600E mice indeed show a high density of TAMs, sug-
gesting that TAMs promote papillary thyroid cancer progression
(Ryder et al., 2008).
The BRAFV600E mutation induces also the expression of genes
involved in matrix remodeling, which could account in part
for the greater predisposition of PTC with BRAF mutation to
invade surrounding tissues (Mesa et al., 2006). In human patients,
PTCs harboring BRAFV600E show a more aggressive clinical-
pathologic behavior, with extrathyroidal extension and a signif-
icant increase in MMP-2, MMP-9, and ICAM-1 protein levels,
suggesting that these proteins may play a role in PTC progression
(Frasca et al., 2008). Furthermore,high levels of CXCR4 expression
were found in BRAFV600E-positive PTCs, and CXCR4 expression
was associated with thyroid capsule inﬁltration and extrathyroidal
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extension (Torregrossa et al., 2011). These ﬁndings await in-depth
mechanistic analysis in the BRAFV600E mouse model.
Finally, an expression proﬁle study of murine PDTCs derived
from BRAFV600E transgenic mice showed an unequivocal signa-
ture of epithelial-to-mesenchymal transition (EMT; Knauf et al.,
2011). EMT involves changes in epithelial cells that disassem-
ble their junctional structures, express mesenchymal proteins,
remodel their extracellular matrix, lose polarity, and become
more migratory. Thus, this model will allow a more mecha-
nistic approach to the problem of thyroid cancer dedifferen-
tiation and progression to poorly differentiated and anaplastic
tumors.
Although this ﬁrst mouse model of BRAFV600E-positive PTC
recapitulates the phenotype of human PTCs, it displays severe
hypothyroidism that is not usually present in humans. A recent
paper describes a novel inducible PTC model (Thyro::CreERT2;
BRafCA) in which widespread Cre-induced BRAF activation gen-
erates the same tumor and hypothyroid phenotype as the older
model. However, stochastic tamoxifen-independent Cre activity
induces localized lesions without concurrent hormonal derange-
ment. Therefore this model may be, in some aspects, a more
accurate model of human PTC (Charles et al., 2011).
The recent development of novel small-molecule inhibitors tar-
geting BRAFV600E may provide selective and rational advantages
for the treatment of patients with PTC harboring this mutation.
In particular, two Plexxikon compounds, PLX4720 and PLX4032,
are novel, orally available selective small-molecule inhibitors of
BRAFV600E that have been speciﬁcally designed to insert into the
ATP-binding site and trap oncogenic BRAFV600E in an inactive
conformation. These compounds have shown an important effect
in a cohort of melanoma patients (Bollag et al., 2010).
In thyroid tumors, in vitro treatment of BRAFV600E-positive
thyroid cancer cell lines with PLX4720 resulted in cell cycle
arrest, whereas RET/PTC1 and RAS mutated thyroid cancer cell
lines were resistant to inhibition even at high concentrations
(Salerno et al., 2010). Furthermore, PLX4720 markedly inhib-
ited tumor growth and metastasis in an orthotopic mouse model
of human ATC harboring BRAFV600E (Nucera et al., 2011).
PLX4032 is being tested in human BRAFV600E carriers. Early
results show one partial response and two patients with a brief
stable disease among the three PTC patients analyzed in a phase
I trial (Flaherty et al., 2010). Accordingly, evidence is accu-
mulating that BRAFV600E tumors rapidly develop resistance to
BRAF inhibitors (Nazarian et al., 2010). In vivo studies using
the aforementioned mouse models will shed more light on the
mechanisms implicated in resistance development, and on the
possibility of overcoming resistance by targeting the pathways
involved.
FTC PROGRESSION MODELS
Follicular thyroid carcinoma (FTC) represents the second largest
subtype of thyroid malignancies, and is more prevalent in areas
of dietary iodine deﬁciency (Schlumberger, 1998). FTC patients
have a poorer outcome than those affected with PTC since they
are less likely to take up radioactive iodide for imaging and thera-
peutic ablation (Jonklaas et al., 2006). Histologically, FTCs display
variable morphology ranging from small/medium-sized follicles
containing colloid to trabecular or solid growth pattern (Schlum-
berger, 1998). It is extremely rare for a FTC to be composed of
macrofollicles (Fonseca et al., 2006).
The major molecular features of FTC are the prominence of
aneuploidy and the high prevalence of RAS mutations and of
PAX8–PPARγ rearrangements, the latter as a result of a chro-
mosome 2;3 translocation (DeLellis, 2004). The PAX8–PPARγ
rearrangement leads to in-frame fusion of exon 7, 8, or 9 of PAX8
on 2q13 with exon 1 of PPARγ on 3p25 (Kroll et al., 2000). This
translocation creates a fusion gene composed by the DNA-binding
domain of the thyroid transcription factor PAX8 and domains A
to F of the nuclear receptor PPARγ (Eberhardt et al., 2010). The
exact mechanism by which this rearrangement leads to a carcino-
genic phenotype is not fully understood. It appears as though the
PAX8–PPARγ chimeric protein inactivates the wild-type PPARγ,
which is a putative tumor suppressor (Suh et al., 1999; Chang and
Szabo, 2000).
Follicular neoplasms are also often characterized by PI3K/AKT
alterations. Phosphorylation of AKT, the key player in this path-
way, is far more frequent than that of ERK in FTCs (Xing, 2010).
The aneuploid pattern and the various molecular alterations
detected in FTCs support the assumption that the development
of such tumors is the endproduct of multiple oncogenic steps,
thus justifying their usual appearance as single neoplasms (Fagin,
2002).
Most models for FTC were established based on the genetic
alterations described in human tumors such as Ras mutations and
PAX8–PPARγ rearrangement. However, mouse models based on
these genetic alterations have failed to fully recapitulate human
FTC. Instead, genetically engineered models carrying a thyroid
hormone receptor β mutant (TRβPV/PV) and deletion of the Pten
tumor suppressor have become the tool of choice to study the
development of FTC.
TRβPV/PV MODELS
Thyroid hormone receptors (TRs) are ligand-dependent tran-
scription factors that have a central role in cell proliferation,
differentiation, and apoptosis. They are members of the steroid
hormone/retinoic acid nuclear receptor superfamily. Two genes,
TRα and TRβ, located on human chromosome 17 and 3, respec-
tively, encode for four thyroid hormone (triiodothyronine T3)
binding receptors (TRα1, TRβ1, TRβ2, and TRβ3) and two non-
T3-binding receptors (TRα2 and TRα3). These TRs are expressed
in a tissue-dependent and developmentally regulated pattern
(Cheng, 2000). Mutations of the TRs can cause a potent dom-
inant negative action (Lin et al., 1999). Furthermore, multiple
mutations in both TRα1 and TRβ1, with impairment in T3 and
DNA binding and loss of transcriptional activity, were detected in
human renal clear cell carcinoma (Kamiya et al., 2002). Unusually
high frequencies of mutations in TRβ1 and TRα1 were also found
in a subset of human PTC (93.75 and 62.25%, respectively, of 16
tumors examined; Puzianowska-Kuznicka et al., 2002).
Kaneshige et al. (2000) generated a mutant knock-in mouse
expressing a potent dominant negative TRβ1 mutant, PV (TRβPV
mice). The PV mutation was identiﬁed in a patient with thyroid
hormone resistance syndrome (RTH; Parrilla et al., 1991; Weiss
and Refetoff, 2000). RTH is a genetic disease caused by mutations
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of the TRβ gene (Weiss and Refetoff, 2000). Most patients with
RTH are heterozygotes with only one mutant TRβ allele (Weiss
and Refetoff, 2000). Patients with RTH exhibit dysfunction of the
pituitary–thyroid axis,with high circulating levels of TSH and thy-
roid hormones (T3 and thyroxine T4; Weiss and Refetoff, 2000).
PV has a unique mutation in exon 10, a C-insertion at codon 448,
which causes a frameshift of the carboxy-terminal 14 amino acids
of TRβ1, resulting in total loss of T3-binding and transcriptional
activation (Meier et al., 1992).
TRβPV mice faithfully reproduce human RTH because they
exhibit mild disruption of the thyroid–pituitary axis and a severe
dysfunction of the pituitary–thyroid axis (Kaneshige et al., 2000).
In addition, TRβPV/PV homozygotes develop follicular cell hyper-
plasia by 3weeks of age and invasive FTCs by 4–5months of age.
They also display metastases to the lungs and heart by 5months
of age, and the metastases often have foci of anaplasia consisting
of spindle-shaped cells (Suzuki et al., 2002). This mouse model
offers a fairly good recapitulation of human follicular carcinoma
arising from hyperplastic goiter, but it differs in that these mice
have elevated circulating T3 and T4 levels, while human FTCs are
infrequently functional (Kaneshige et al., 2000).
Kato et al. (2004) crossed TRβPV mice with TRβ−/− mice. As
TRβPV/− mice aged, they also spontaneously developed FTC after
progression from hyperplasia, with local invasion, anaplasia, and
metastasis to the lungs (Kato et al., 2004). The pathological pro-
gression of thyroid carcinoma in TRβPV/− mice was identical to
that in TRβPV/PV mice, and the patterns in the alteration of signal-
ing pathways were also similar to those observed inTRβPV/PV mice
during thyroid carcinogenesis (Kato et al., 2004). These results
point out that TRβ may function as a tumor suppressor, since, in
the absence of a wild-type allele, the PV mutation in one TRβ
allele is sufﬁcient for the mutant mice to spontaneously develop
FTC.
One of the overexpressed genes in mice carrying the TRβPV/PV
genotype is the pituitary tumor-transforming gene (PTTG),which
has been previously associated with tumorigenesis (Ramaswamy
et al., 2003). To evaluate the role of PTTG in thyroid carcino-
genesis, Kim et al. (2007b) analyzed the offspring of TRβPV mice
crossed with mice lacking PTTG (PTTG−/−mice). The thyroids
of TRβPV/PV PTTG−/− mice resulted signiﬁcantly smaller than
those of TRβPV/PV mice, with a decrease in thyroid prolifera-
tion.Histological analysis showed no difference in FTCoccurrence
betweenTRβPV/PV andTRβPV/PV; PTTG−/− mice, which indicates
that PTTG deletion does not prevent the initiation of FTC. How-
ever, TRβPV/PV, PTTG−/− mice exhibited a signiﬁcant decrease
in vascular invasion and less development of lung metastasis as
they aged. CD31 staining also showed a decrease in vessel den-
sity inTRβPV/PV;PTTG−/− versusTRβPV/PV thyroids, highlighting
the dual roles of PTTG as a regulator of thyroid growth and
contributor of tumor progression (Kim et al., 2007b).
Kim et al. (2007a) also tested the role of gelsolin, an actin-
regulatory protein, which had been previously found down-
regulated in the mutant mice and in many other cancers such
as breast (Winston et al., 2001), bladder (Tanaka et al., 1995), lung
(Dosaka-Akita et al., 1998), and prostate (Lee et al., 1999). The
results of these studies showed that there was an age-dependent
reduction of gelsolin protein abundance in TRβPV/PV mice as
tumorigenesis progressed. Knockdown of gelsolin by small inter-
fering RNA resulted in increased tumor cell motility whereas an
increase in gelsolin expression led to decreased cell motility (Kim
et al., 2007a). Further biochemical analysis demonstrated that gel-
solin physically interacts with the DNA-binding domain TRβ1
or PV in vivo and in vitro, and that the interaction with PV
reduces gelsolin’s binding to actin, leading to disarrayed cytoskele-
tal architectures (Kim et al., 2007a). These results suggest that PV-
induced alterations of the actin/gelsolin cytoskeleton contributes
to increased cell motility that contributes to the local tumor
progression and metastatic potential of thyroid carcinogenesis.
Since the TRβPV/PV mice exhibit highly elevated TSH levels,
Lu et al. (2010) crossed the TRβPV/PV mice with TSHR knock-
out mice (TSHR−/− mice) to eliminate the effect of TSH–TSHR
signaling during carcinogenesis. They found that the thyroid of
TRβPV/PV TSHR−/−mice exhibited impairment in growth and did
not develop tumors. However, TSH signaling, while necessary, was
not sufﬁcient for transformation, sincewild-typemice treatedwith
the goitrogen PTU had a 9.1-fold higher serum TSH level than
TRβPV/PV mice, but the degree of thyroid pathology was less than
that of TRβPV/PV mice at the same age (Lu et al., 2010).
The PI3K/AKT pathway is activated in both the thyroid and
metastatic lesions of theTRβPV/PV mousemodel (Kim et al., 2005).
Since the activation of the PI3K/AKT signaling cascade contributes
to thyroid carcinogenesis, this pathway becomes a potential ther-
apeutic target in FTC.When the TRβPV/PV mice were treated with
LY294002 (LY), a potent PI3K inhibitor, a decrease in cyclin D1
expression was observed (Furuya et al., 2007). Concomitantly, the
mice displayed an increase in p27Kip1 expression to inhibit thyroid
tumor growth and reduce tumor cell proliferation. LY treatment
increased caspase-3 and decreased phosphorylated-BAD to induce
apoptosis. In addition,LY treatment reduced theAKT–matrixmet-
alloproteinase 2 signaling with a decrease in cell motility to block
metastatic spread of thyroid tumors (Furuya et al., 2007). There-
fore, this treatment effectively prolonged the survival of TRβPV/PV
mice, providing the ﬁrst preclinical evidence of the in vivo efﬁcacy
of PI3K inhibition in the treatment of FTC.
More recently, tumor development, progression, and metas-
tasis were analyzed in the TRβPV/PV; Akt1−/− mouse model
(Saji et al., 2011). PV-dependent thyroid hyperplasia occurred in
both groups Akt1 WT and KO mice; however, the thyroid size
was greater in the WT mice. On the other hand, thyroid can-
cer development was delayed in the KO mice and the degree
of tumor invasiveness was reduced (Saji et al., 2011). The WT
mice displayed pulmonary metastases at 12 and 15months of
age, while KO mice did not. In spite of sustained expression of
Akt2 or Akt3, pAkt levels were decreased, suggesting that thy-
roid cancer development and progression in TRβPV/PV mice are
Akt1-dependent.
Along the same pathway, to assess how Pten deregulation con-
tributes to the PV phenotype, TRβPV/PV, Pten+/− mice were gen-
erated and analyzed (Guigon et al., 2009). These studies demon-
strated that Pten deﬁciency accelerated the progression of thy-
roid tumors and increased the occurrence of metastases to the
lungs in the PV mice, thereby signiﬁcantly reducing their sur-
vival as compared with TRβPV/PV, Pten+/+ mice (Guigon et al.,
2009). AKT activation was concomitantly increased by twofold in
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TRβPV/PV, Pten+/− thyroids, leading to increased activity of the
downstream mammalian target of rapamycin (mTOR)–p70S6K
and decreased activity of the forkhead family member FOXO3a.
In addition, cyclin D1 expression was increased, and apoptosis
was decreased as indicated by increased expression of nuclear
factor-κB (NF-κB) and decreased caspase-3 activity (Guigon et al.,
2009). Guigon et al. also analyzed the effect of a treatment with a
speciﬁc mTORC1 inhibitor (RAD001) in the TRβPV/PV, Pten+/−
mouse model. Although the treatment did not prevent capsular
and vascular invasion and the occurrence of lung metastases, it
considerably reduced thyroid tumor growth, there by prolonging
the mice’s life span. RAD001 induced a signiﬁcant decrease in cell
proliferation that was linked to the reduced amount and altered
activity of key regulators of cell cycle progression (Guigon et al.,
2010).
The steroid receptor activator-3 (SRC-3) is a member of the
p160 family that complexes with members of the steroid/thyroid
hormone receptor superfamily to modulate their transcriptional
activity (Liao et al., 2002; Lonard and O’Malley, 2005). It is ampli-
ﬁed in breast and ovarian cancer (Anzick et al., 1997) and over-
expressed and/or ampliﬁed in other steroid hormone-sensitive
tumors, such as prostate cancer andmeningioma, as well as steroid
hormone-independent tumors, such as pancreatic cancer, colorec-
tal carcinoma, and hepatocellular carcinoma (Yan et al., 2006).
Transgenic mice overexpressing SRC-3 display many types of
malignancy in several tissues, such as mammary gland, pituitary,
uterus, lung, and liver, through activation of the insulin growth
factor (IGF)/AKT signaling (Torres-Arzayus et al., 2004). To deter-
mine its effects on thyroid carcinogenesis,Ying et al. (2008) crossed
TRβPV/PV mice with SRC-3 null mice to evaluate thyroid tumor
development and progression. TRβPV/PV mice deﬁcient in SRC-
3 (TRβPV/PV SRC-3−/− mice) exhibited signiﬁcantly increased
survival, decreased thyroid tumor growth, delayed tumor progres-
sion, and lower incidence of distant metastasis as compared with
TRβPV/PV, SRC-3+/+ mice (Ying et al., 2008). Additional in vivo
and in vitro analyses showed that SRC-3 deﬁciency leads to inhibi-
tion of cell cycle progression by controlling the expression of E2F1,
could induce apoptosis through the control of the expression of
Bcl-2 and caspase-3, and ﬁnally could suppress neovascularization
and metastasis (Ying et al., 2008).
PTEN−/−MODELS
Despite all the correlative data regarding the PI3K/AKT signaling
cascade in the control of normal thyroid function and the link
between its deregulation and thyroid disease, the aforementioned
pathogenetic models still lacked direct in vivo evidence support-
ing their validity. To address these issues, we have generated a
mouse strain in which the Pten gene is selectively deleted in the
thyroid follicular cells by Cre-mediated recombination. This leads
to constitutive activation of the PI3K/AKT pathway and repro-
duces the genetic events taking place in the nodular lesions and
thyroid carcinomas developing in Cowden disease patients, who
carry a heterozygous germline mutation in PTEN. Pten mutant
mice develop from birth diffuse goiter characterized by extremely
enlarged follicles, in the presence of normal TSH and T4 hormone
levels (Yeager et al., 2007). A unique feature of this model is the
differential proliferative advantage of mutant thyrocytes between
genders, mimicking the increased incidence of thyroid disease in
women (Yeager et al., 2007; Antico-Arciuch et al., 2010).
Surprisingly, goitrogen treatment did not cause a substantial
increase of the mutant thyroid size and increased only to some
extent the proliferation index of the female thyrocytes, suggesting
that a relevant part of the TSH-induced proliferation signals are
conducted through the PI3K/AKT cascade (Yeager et al., 2007),
converging on mTOR (Yeager et al., 2008).
Complete loss of Pten leads to invasive tumors in over 50%
of the mutant females and 35% of the mutant males aged 1 year
(Antico-Arciuch et al., 2010). These data show that Akt activa-
tion is sufﬁcient, in vivo, to induce thyroid hyperplasia and diffuse
colloid goiter in young mice by increasing the thyroid mitotic
index,and that it needs additional genetic alterations for neoplastic
transformation to occur in older mutants.
Thyroid cancer originating from the follicular epithelium often
displays activating mutations of Ras family members (Shi et al.,
1991). Although several transgenic approaches have been used
in the past to deﬁne the molecular mechanisms of Ras-mediated
thyroid transformation, it is now clear that supraphysiologic
expression in transgenic systems does not resemble the activity
of oncogenic Ras when expressed at endogenous levels (Feunteun
et al., 1997; Tuveson et al., 2004; Vitagliano et al., 2006).
The frequencies and overlap of genetic alterations in the PI3K
and Ras/MAPK cascades increase with progression from differ-
entiated to undifferentiated thyroid tumors: alterations in PI3K
and MAPK pathways occur in nearly all undifferentiated tumors,
with themajority of the cases harboring genetic alterations in both
pathways (Hou et al., 2007).
To gain insights into how PI3K activation cooperates with acti-
vation of Ras in promoting thyroid cancer pathogenesis, the Kras
mutant allele, G12D, was conditionally expressed in the thyroid
epithelium through Cre-mediated deletion of a ﬂoxed STOP cas-
sette preventing KrasG12D expression in mice that had already
Pten deleted (Miller et al., 2009). Although each of these two path-
ways, alone, was unable to transform thyroid follicular cells, their
simultaneous activation was highly oncogenic, leading to invasive,
and metastatic follicular carcinomas (Miller et al., 2009). In par-
ticular, PI3K activation suppressed Kras-initiated feedback signals
that uncouple MEK and ERK activation, thus inhibiting MAPK
activity; in addition, PI3K and Kras cooperated to dramatically
up-regulate cyclin D1 mRNA levels (Miller et al., 2009). Finally,
combined pharmacologic inhibition of PI3K and MAPK com-
pletely abolished the growth of double-mutant transformed cell
lines, providing a strong rationale for the dual targeting of these
pathways in thyroid cancer (Miller et al., 2009).
Cell cycle progression is accomplished by a sequential and con-
certed activation of a family of serine–threonine kinases, named
the cyclin-dependent kinases (CDKs). p27Kip1 is an essential CDK
inhibitor and plays a fundamental role in key cellular processes
such as proliferation, differentiation, apoptosis, substrate adhe-
sion, and motility. Downregulation of p27Kip1 nuclear level or its
cytosolic localization are always correlated with poor prognosis of
numerous types of human epithelial and non-epithelial cancers
(Borriello et al., 2011).
When analyzing the outcome of thyroid-speciﬁc Pten−/−;
p27−/− mice, the double-mutant animals exhibited a decrease of
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their survival, and all died by 6months of age, with dramatically
hyperplastic thyroids that caused dyspnea and prevented feed-
ing (Antico-Arciuch et al., 2010). Interestingly, Pten−/−; p27+/−
mutants had a mean survival of 58weeks, a 25% reduction com-
pared to Pten−/−; p27+/+mice. While Pten−/−; p27+/+females
show a marked decrease in life span compared to single mutant
males, these gender-based differences in survival were totally res-
cued by the reduction of p27 gene dosage, suggesting that p27 is
a relevant mediator of the effects of estrogen on thyroid tumor
incidence (Antico-Arciuch et al., 2010). In fact, when we com-
pared the proliferative index of thyroids from young, tumor-free
Pten−/−; p27+/+ and Pten−/−; p27+/− mice, we observed that
loss of one p27 allele in the males resulted in a larger prolifer-
ation increase than it did in the females. As a consequence, the
gender differences in thyrocyte proliferation were considerably
reduced in Pten−/− p27+/− mice. Furthermore, Pten−/−; p27+/−
compound mutants survived long enough to develop adenomas
and carcinomas (Antico-Arciuch et al., 2010). These compelling
data strongly support a role for p27 as an important mediator
of estrogen signaling in thyroid hyperproliferation and neoplastic
transformation.
CONCLUSION
Despite some shortcomings associated with a number of bio-
logical differences between mice and humans, the last 15 years
have seen the development of a variety of genetically deﬁned
models of well differentiated thyroid tumors that have dramat-
ically increased our knowledge of the key molecules and pathways
involved in both neoplastic transformation and tumor progres-
sion. The challenge is now twofold: to extend thesemodels tomore
aggressive tumor types (i.e., anaplastic carcinomas), in order to
identify the speciﬁc mechanisms leading to loss of differentiation
and increasedmetastatic potential; and to exploit thesemodels and
available cutting edge technology to pinpoint keymolecular nodes
that can be targeted in order to increase or restore therapeutic
efﬁcacy.
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